HGH Frag 176-191
Also known as hGH fragment 176-191, AOD9604 (modified analogue)
A synthetic peptide from the C-terminal region of human growth hormone, studied for effects on fat metabolism separate from GH's growth actions.
Preclinical research
Size
1 option- Catalog no.
- —
- Specification
- 5mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
HGH fragment 176-191 corresponds to amino acids 176 to 191 at the C-terminal end of human growth hormone. Early research found that this region carries some of GH's effects on lipid metabolism without its effects on growth or blood glucose. Rodent studies of the fragment and its tyrosine-modified analogue, AOD9604, reported increased fat oxidation and reduced fat accumulation in obese mice. It does not activate the growth hormone receptor in the way full-length GH does.
Class: C-terminal fragment of human growth hormone
Mechanism of action
How the compound acts, as described in the literature.
Represents the C-terminal 176–191 region of human growth hormone, studied for lipolytic and antilipogenic activity.
Rodent work reported reduced lipogenesis and increased lipolysis and fat oxidation in adipose tissue.
It is reported not to stimulate IGF-1 production or the growth-promoting effects of full GH.
Its effects on lipid metabolism in mice were examined in relation to beta-3 adrenergic receptor pathways.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
1993
Preclinical study
PMID 8358331Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone.
Wu Z, et al. · Biochem Mol Biol Int
Reported that a synthetic peptide from the C-terminal sequence of human GH reduced lipogenesis, supporting a metabolic role for this region.
2001
Rodent study
PMID 11673763Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
Heffernan MA, et al. · Int J Obes Relat Metab Disord
In obese mice, chronic treatment with human GH or a modified C-terminal fragment increased fat oxidation and reduced body weight.
2001
Rodent study
PMID 11713213The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Heffernan M, et al. · Endocrinology
Compared GH and AOD9604 effects on lipid metabolism in obese and beta-3 adrenergic receptor knockout mice, examining the receptor pathways involved.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
Evidence is mainly from rodent studies. No indexed human trial has shown efficacy for the fragment or its analogue AOD9604 in weight loss, and much recent literature on it concerns anti-doping detection. It is not approved for any use.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| — | HGH Frag 176-191 | 5mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.